香港, 2026年3月26日 - (亚太商讯 via SeaPRwire.com) - 3月25日，小鹏汇天 X3-F（陆地航母）飞行汽车所搭载的顶流圆柱电池系统在中创新航成都工厂量产下线。据了解，此次下线的动力电池产品应用了中创新航全球首创的“顶流圆柱”电池技术。该“顶流”高能飞行电池，能量密度达360Wh/kg，是行业能量密度最高的固液混合圆柱电池，在高安全性、高功率密度与高能量密度之间实现了卓越平衡，严格满足航空级安全标准，将配套应用于小鹏汇天多款飞行汽车。双方合作始于2022年，中创新航助力小鹏汇天完成了全球首个电动垂起飞行汽车的首飞。在历经了一系列严苛验证之后，中创新航电池产品的可靠性得到了充分检验。以此为契机，中创新航组织优势科研力量，重点布局下一代“顶流圆柱”电池，针对一系列基础科学和技术难题组织了专项攻关，并牵头联合小鹏汇天等优势单位获得国家重点研发计划项目支持，切实推动了相应航空动力电池本征安全与高比能技术的国际领先。基于此，双方于2025年4月签署深化战略合作协议，确立下一代机型的独家供应关系。从牵头国家重点研发计划攻关“顶流圆柱”技术，到此次飞行汽车电池率先实现量产落地，中创新航在前瞻性新兴赛道的布局正加速兑现。多元化应用场景中的商业化能力的持续夯实，为其在下一代能源技术竞争中打开了新的增长空间。 Copyright 2026 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

TransNusa To Operate Additional Frequencies for Both Singapore-Jakarta and Singapore-Bali Routes- Additional frequencies respond to strong demand for travel between Indonesia and Singapore while strengthening regional connectivity- Both routes received additional scheduled flight slots, providing TransNusa passengers options for day travel- TransNusa increases its minimum baggage allowance to 20kgs, in addition to the 7kg hand carry for it’s minimum package bundle, SEAT, and increased minimum baggage allowance to 30kgs for its highest bundle, Flexi-ProJAKARTA, Mar 25, 2026 - (ACN Newswire via SeaPRwire.com) - PT TransNusa Aviation Mandiri (TransNusa) today announced the launch of additional scheduled flights between Jakarta and Singapore as well as Jakarta and Bali, further strengthening connectivity between two of Southeast Asia’s paramount business and tourism travel hubs.TransNusa Group Chief Executive Officer, Datuk Bernard Francis said that the additional scheduled flight between Soekarno–Hatta International Airport in Jakarta and Singapore Changi Airport will start on April 17 while the additional flight from Gusti Ngurah Rai International Airport in Bali to Changi Airport will start on May 2. Sale of tickets for both additional scheduled flights started on March 17 and can be bought directly from transnusa.co.id or on any main online travel agency platform.The additional flights are part of the TransNusa’s broader strategy to expand regional connectivity and respond to the growing demand for travel between Indonesia and Singapore—two markets with strong economic, cultural, and tourism ties.“Singapore is one of the region’s vital aviation and commercial hub, and these additional flights will provide travellers with greater flexibility while supporting trade and tourism between the two countries,” Datuk Bernard added.“The Jakarta–Singapore corridor is one of the busiest international routes in the region, serving millions of travellers each year. By increasing capacity on this route, we aim to provide a more seamless connections for passengers traveling across Southeast Asia and beyond,” Datuk Bernard stressed, adding that TransNusa’s passengers will benefit from improved scheduling options, allowing for easier same-day connections to a wider network of destinations.“Our goal is to continue improving accessibility across Southeast Asia by increasing frequencies on high-demand routes,” explained Datuk Bernard.Flight DetailsTransNusa’s additional scheduled flight, 8B 155, will depart Jakarta at 07.45pm from Soekarno-Hatta International Airport in Jakarta and arrive at the Singapore Changi Airport at 10.25pm. The flight, 8B 156, will depart Singapore Changi Airport at 11.20pm and arrive at Soekarno-Hatta International Airport in Jakarta at 12.10am.With the launch of this news additional Frequency, TransNusa will be operating three daily flights from Jakarta to Singapore effective April 17, 2026.On the Bali-Singapore route, TransNusa's new scheduled flight, 8B 553, will depart the Gusti Ngurah Rai International Airport at 10.20am and arrive at Changi Airport at 01.15pm. Meanwhile, TransNusa’s flight, 8B 554, will depart Changi Airport at 02.15pm and arrive back at the Gusti Ngurah Rai International Airport in Bali at 05.55pm.TransNusa will be utilising its Airbus A320 for both the international routes.TransNusa, which aims to ensure its passengers travel with ease and comfort, has configured its A320 aircrafts with a 174-seat configuration, which allows for passengers to enjoy about 30 inches of legroom, comparable to the experience passengers would get in a full-service airline."We are committed to providing affordable and competitive ticket prices, while still providing premium services to our customers,” stressed Datuk Bernard.For its international flights, TransNusa not only provides premium services with competitive ticket prices, but the airline also has attractive product bundles called SEAT, SEAT-PLUS and FLEXI-PRO."Our SEAT passengers will now enjoy check-in baggage of 20kgs,” Datuk Bernard said, explaining that the baggage offering was over and above the 7kgs limit offered as a passenger’s hand carry.“For the highest package, FLEXI-PRO, we have increased our baggage allowance to 30kgs, free to choose seats, free food, and drinks, and priority boarding. In addition, TransNusa also provides its FLEXI-PRO passengers with the flexibility to change their flight schedule without restrictions and obtain refund when needed,” concluded Datuk Bernard.About TransNusaTransNusa Airline, is a Premium Service Carrier. In February 2024, the airline rebranded itself to a Premium Service Carrier in line with its upgraded aircrafts that offers better comfort as well as based on the flexibility and quality of the services offered. TransNusa, which received its AOC certification on 9th September 2022, launch its first three A320 operations on 6th October, 14th October and 12th December, 2022.In 2023, TransNusa introduced a new business model making it the first Premium Service Carrier in the Asia Pacific region. TransNusa introduced its first international flight on 14th April, 2023. The airline is currently based in Jakarta and Bali.On the international front, TransNusa flies to Singapore, Guangzhou, Kuala Lumpur, Perth, Shanghai, and Shenzhen. The airline became the second Indonesian airline to fly to China and the first Indonesian airline to launch a Premium Service Carrier business model. Passengers can book their flights on the TransNusa website at www.transnusa.co.id, through any secure online travel agent, through authorized travel agents in Singapore and Indonesia.Primary International Media ContactTrina Thomas RajMobile: +6012 4992672E-mail: trina@myqaseh.org Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

CLEVELAND, Ohio, Mar 26, 2026 - (ACN Newswire via SeaPRwire.com) - Formerra, a leader in performance materials distribution, announced the implementation of a transportation surcharge to address continued cost escalation across the Americas freight and logistics market. Beginning April 1, 2026, a $350 per delivery surcharge will apply to all shipments.The freight and logistics market continues to experience elevated costs driven by rising diesel prices, evolving regulatory requirements affecting driver availability, tighter trucking capacity, and increasing operating expenses across the logistics sector. Industry forecasts indicate these pressures will persist for the foreseeable future."Maintaining reliable service for our customers requires us to adapt to sustained shifts in the transportation landscape," said Tom Kelly, Formerra CEO. "This surcharge is necessary to address these industrywide cost pressures that are outside of our control while continuing to provide the high service levels customers expect from Formerra."Customers should contact their Formerra representative for more information.About FormerraFormerra is a preeminent distributor of engineered materials, connecting the world's leading polymer producers with thousands of OEMs and brand owners across healthcare, consumer, industrial, and mobility markets. Powered by technical and commercial expertise, it brings a distinctive combination of portfolio depth, supply chain strength, industry knowledge, service, leading e-commerce capabilities, and ingenuity. The experienced Formerra team helps customers across multiple industries to design, select, process, and develop products in new and better ways - driving improved performance, productivity, reliability, and sustainability. To learn more, visit www.formerra.com.Media ContactJackie MorrisFormerraMarketing Communications Managerjackie.morris@formerra.com+1 630-972-3144SOURCE: Formerra Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

俄亥俄州克利夫兰, 2026年3月26日 - (亚太商讯 via SeaPRwire.com) - 高性能材料分销领域的领导者Formerra宣布，将征收运输附加费，以应对美洲货运和物流市场持续上涨的成本。自2026年4月1日起，所有货运将收取每次350美元的附加费。受柴油价格上涨、影响司机供应的监管要求变化、卡车运输能力趋紧以及物流行业整体运营成本上升等因素驱动，货运和物流市场的成本持续攀升。行业预测显示，这些压力在可预见的未来仍将持续。“为了向客户维持可靠的服务，我们必须适应运输行业持续发生的变革，”Formerra首席执行官汤姆·凯利（Tom Kelly）表示。“实施这项附加费是必要的，旨在应对这些超出我们控制范围的行业性成本压力，同时继续提供客户所期待的Formerra高水准服务。”客户如需了解更多信息，请联系您的 Formerra 代表。关于 FormerraFormerra 是工程材料领域的顶尖分销商，致力于将全球领先的聚合物生产商与医疗保健、消费品、工业及移动出行市场中的数千家原始设备制造商（OEM）和品牌所有者紧密连接。凭借深厚的技术与商业专长，Formerra 融合了产品组合的深度、强大的供应链、行业洞察、优质服务、领先的电子商务能力以及创新精神，形成独特的综合优势。Formerra经验丰富的团队助力多行业客户以创新且更优的方式进行产品设计、选型、加工与开发，从而提升产品性能、生产效率、可靠性和可持续性。了解更多信息，请访问 www.formerra.com 。媒体联系Jackie MorrisFormerra市场传播经理jackie.morris@formerra.com+1 630-972-3144来源：Formerra Copyright 2026 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

Toronto, ON, Mar 25, 2026 - (ACN Newswire via SeaPRwire.com) - Aleen Inc. (CSE: ALEN-U), a digital wellness company, has introduced a new data layer within its Personal Wellness Account, designed to enhance how its AI assistant interprets and structures wellness data.As part of its ongoing product development, Aleen Inc. has implemented a biomarker extraction approach that enables the system to process user-provided data and identify key indicators in a more structured way. This includes the use of a dedicated AI agent that processes documents page by page and extracts relevant biomarkers from wellness data sources.In addition to extraction, Aleen Inc. is developing a standardized structure for each biomarker, including its name, value, unit of measurement, and reference range. These structured data elements are now reflected within the Personal Wellness Account interface. Users will be able to view the total number of detected biomarkers and potential deviations directly within the file list, while a dedicated “Biomarkers” tab in the detailed view provides expanded access to the data in both table and panel formats, along with search and filtering capabilities.This development represents a step toward more structured data environments within Aleen’s ecosystem, supporting improved organization, accessibility, and interaction with wellness data. The introduction of this layer may also contribute to future enhancements in how the system identifies patterns and supports user-centered insights. This update reflects Aleen Inc.’s continued focus on building scalable data architecture and advancing its Personal Wellness Account as a structured, AI-assisted environment for working with wellness data.About Aleen Inc.Aleen Inc. operates as a digital wellness and well-being insights company. Its platform transforms personal wellness information into simple, personalized insights that promote greater self-awareness and balance in daily life. Aleen’s mission is to empower individuals with knowledge and clarity through responsible use of technology and data.For more information, visit www.aleen.ca.Forward-Looking StatementThis press release contains forward-looking statements regarding future plans and developments by Aleen Inc. These statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially. Aleen Inc. undertakes no obligation to update or revise these statements except as required by law. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HONG KONG, Mar 25, 2026 - (ACN Newswire via SeaPRwire.com) - On March 25, 2026, Hengrui Pharma (600276.SH; 01276.HK) announced robust financial results for the full year 2025, fueled by its dual strategy of innovation and globalization. Revenue increased 13.02% year-on-year to RMB 31.63 billion, and net profit attributable to shareholders increased by 21.69% to RMB 7.71 billion.Innovation remained the engine of Hengrui’s growth: Innovative drug sales increased by 26.09% year-on-year to RMB 16.34 billion, contributing 58.34% to total drug sales. This was driven by a robust pipeline across therapeutic areas, with oncology products contributing RMB 13.24 billion in revenue (+18.52% YoY), and non-oncology products contributing RMB 3.10 billion in revenue (+73.36% YoY).Hengrui kept innovation at its core, with R&D expenditure reaching RMB 8.72 billion in 2025, accounting for 27.58% of total revenue, of which RMB 6.96 billion was expensed. During the year, the company secured seven approvals for Class 1 innovative drug, one for a Class 2 innovative drug, and six for new indications of marketed innovative drugs. The pace of regulatory progress accelerated with 15 NDA/BLAs accepted by the NMPA. Meanwhile, 28 drug candidates entered Phase III clinical trials, 61 progressed to Phase II, and 28 NMEs entered Phase I for the first time.The company currently has over 100 proprietary innovative products in clinical development and is conducting more than 400 clinical trials. This robust portfolio will be further supported by approximately 53 innovative product and indication approvals anticipated during 2026-2028.2025 marked another year of accelerated progress in Hengrui's global expansion. Licensing revenue rose 25.62% to RMB 3.39 billion, cementing the growing global recognition and value of the company’s innovative portfolio. During the year, the company completed five overseas business development transactions for innovative drugs with leading MNCs and biotechs, highlighted by a strategic collaboration with GSK. In parallel, the company continued to advance its self-developed assets and global regulatory efforts. Multiple innovative drugs had their first global clinical trials initiated, ranging from Phase I to III.Additionally, Hengrui successfully listed on the Hong Kong Stock Exchange, raising total gross proceeds of HK$11.4 billion (US$1.5 billion), including the over-allotment option — marking the largest pharmaceutical IPO in Hong Kong in the past five years and further strengthening its access to global capital.Looking ahead, Hengrui will continue to focus on addressing unmet clinical needs with its differentiated innovative portfolio, placing equal emphasis on independent R&D and open collaboration to expand access to innovative drugs for patients worldwide.About Hengrui PharmaHengrui Pharma is an innovative, global pharmaceutical company dedicated to the research, development and commercialization of high-quality medicines to address unmet clinical needs. Its therapeutic areas of focus include oncology, metabolic and cardiovascular diseases, immunological and respiratory diseases, and neuroscience. Driven by a patient-focused philosophy since its founding in 1970, Hengrui Pharma remains committed to advancing human health by striving to conquer diseases, improve health, and extend lives through the power of science and technology.Forward-Looking StatementsThis press release contains forward-looking statements, including statements about the company's future growth prospects and pipeline potential. These statements are based on current expectations and assumptions and do not guarantee future performance. Actual results, developments, and business decisions may differ materially from these forward-looking statements. All information in this press release is as of the date of this press release, and Hengrui undertakes no duty to update such information unless required by law. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HONG KONG, Mar 25, 2026 - (ACN Newswire via SeaPRwire.com) - Everbright Grand China Assets Limited, a property leasing, property management and sales of properties held for sale company under China Everbright Group ("Everbright Grand China Assets" or the "Group", Hong Kong Stock Exchange stock code: 3699) today announced the annual results for the year ended 31 December 2025 (the "Year under Review").During the Year under Review, the Group's revenue was approximately RMB49.9 million (2024: approximately RMB45.9 million), representing a increase of approximately 8.7% as compared to last year, mainly attributable to the increase in total rental income from investment properties. The profit attributable to equity shareholders of the Company amounted to approximately RMB19.5 million (2024: approximately RMB25.3 million), representing an decrease of approximately 22.9% as compared to last year. The decrease in profit was primarily due to the increase in dividend withholding tax and deferred tax expenses recognised in 2025. The Board has proposed to pay a final dividend of RMB1.04 cents per share for the year ended 31 December 2025 (2024: RMB1.05 cents). Together with the interim dividend of RMB0.73 cents per share, the full year dividend amounts to RMB1.77 cents per share (2024: RMB2.17 cents per share).As at 31 December 2025, the Group had current assets of approximately RMB241.0 million (2024: approximately RMB239.9 million). The increase in current assets was mainly a result of [the increase in deposits with maturity of more than three months and cash and bank balances during the year].. The Group had current liabilities of RMB20.1 million (2024: approximately RMB19.9 million). The increase in current liabilities was mainly due to he rise in lease liabilities arising from lease renewals.Property LeasingDuring the year under Review, the rental income from the Group’s property leasing business was approximately RMB34.0 million for the year ended 31 December 2025 (2024: RMB30.5 million). Due to increase in the average rent per square metre, and together with rental subsidies offered to tenants, the total rental income increase. As at 31 December 2025, the Group’s property portfolio comprises three commercial buildings, namely Everbright Financial Center, part of Everbright International Mansion and Ming Chang Building, with a total gross floor area (“GFA”) of approximately 89,507 square meters.Property Management ServiceThe Group provides property management services for its properties, namely Everbright Financial Center and Everbright International Mansion. Revenue from the Group’s property management services was approximately RMB15.9 million for the year ended 31 December 2025 (2024: RMB15.4 million). The increase in revenue from property management services was due to the increase in restaurant income. As at 31 December 2025, the total GFA under the Group’s management was 72,534 sq.m.Investment PropertiesThe Group's investment properties primarily consist of land and/or buildings which are owned or held under a leasehold interest to earn rental income and/or for capital appreciation. As at 31 December 2025, the fair value of the investment properties was RMB979.0 million (2024: RMB967.1 million), representing an increase of approximately 1.23%. For the year ended 31 December 2025, the valuation gain on investment properties amounted to approximately RMB10.3 million (2024: approximately RMB6.6 million).PROSPECTSAs the World Bank noted that despite persistent trade tensions, the global economy has demonstrated stronger-than-expected resilience. Amid a complex environment of mounting external pressures and internal challenges, China continued to advance high-quality development, with the overall economy maintaining stable performance and achieving steady progress. With stable economic growth, corporate demand for commercial space has increased. Coupled with accelerated urbanization and the development of new business districts, demand for commercial properties has continued to rise, supporting the growth of commercial property management and leasing activities. In addition, the Chinese government has introduced a series of favourable policies for the commercial real estate sector, focusing on inventory digestion and optimization of industry planning, thereby providing further support to the property management and leasing industry.The Group’s managed properties mainly comprise commercial assets. Despite macroeconomic conditions and market competition, tenancy arrangements, lease agreements and occupancy rates remained stable in 2025. However, rental levels for newly signed leases were lower than in previous periods. To mitigate the pressure arising from rental adjustments, the Group will continue to enhance customer satisfaction by incorporating value-added services into new lease agreements, including property maintenance and upkeep, facilities management and community event planning.The Group’s existing properties are primarily located in Chengdu, Sichuan and Kunming, Yunnan—two key regional cities—and comprise three commercial buildings: Everbright Financial Center, Everbright International Mansion and Ming Chang Building. Benefiting from their prime locations and high-quality facilities, these properties have attracted a sizable number of state-owned enterprises and large institutions, providing a solid foundation for the Group’s leasing business. In recent years, the Group has successfully introduced tenants from emerging sectors such as software and technology, while also offering digitalised services to tenants. Looking ahead, the Group will continue to promote diversified business development and strive to attract more high-quality commercial tenants.In addition, the further escalation of the situation in the Middle East in March 2026 has led to rising energy prices, heightened inflation expectations and slower economic growth, all of which are core factors affecting overseas investment decisions. Accordingly, the Group will carefully reassess its asset allocation and regional risks with respect to its overseas investment plans. Despite the current significant volatility in the global economy, the Group will adhere to the principle of prudent operation, flexibly seize investment windows, and ensure the safety of capital operations.The Group continues to leverage technology to advance smart property management, enhance operational efficiency and elevate the customer experience. By strengthening digitalisation and refined management capabilities, the Group aims to further improve service quality and customer satisfaction.By fully leveraging the synergy with its parent company, China Everbright Group, while actively developing diversified value-added services to broaden its revenue mix and enhance brand influence. As the industry undergoes transformation and upgrading, the Group remains committed to prudent operations, a strong focus on risk management and internal controls, agile responses to macroeconomic and policy developments, continuous optimisation of its asset portfolio, further strengthening of its resilience against market uncertainties, and also actively explore new development opportunities to create greater value for the shareholders.About Everbright Grand China Assets LimitedEverbright Grand China Assets Limited is engaged in the businesses of property leasing and the provision of property management services under China Everbright Group. It owns, leases and manages properties located in Chengdu, Sichuan province, and also owns and leases a property located in Kunming, Yunnan province. The Group's properties are located in the city centers of Chengdu and Kunming, the key cities of western China. The Group's property portfolio includes three commercial properties, namely Everbright Financial Center, part of Everbright International Mansion and Ming Chang Building. For more information about Everbright Grand China Assets, please visit the Company’s website: https://ebgca.com.hk/.This press release is issued by Porda Havas International Finance Communications Group on behalf of Everbright Grand China Assets Limited.For inquiries, please contact: Kelly Fung+852 2590 1900kelly.fung@pordahavas.co Qin Luk+852 2590 1903samantha.luk@pordahavas.comEmail: ebgca.hk@pordahavas.com Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港, 2026年3月25日 - (亚太商讯 via SeaPRwire.com) - 国元国际发表于 3 月 24 日研究报告表示，亿胜生物科技（1061.HK）2025 年业绩稳健增长，实现营业额 18.14 亿港元，较 2024 年增加 8.6%，主因眼科与外科板块持续发力。其中，眼科收入达 8.35 亿港元（+8.2%），外科收入 8.96 亿港元（+1.8%），医疗保健服务收入激增 350% 至 0.829 亿港元。亿胜生物科技 2025 年溢利较 2024 年增加 3.5% 至 3.18 亿港元。毛利率为 89.2%，处行业高位。现金及等价物增至 7.83 亿港元（+40.5%）。公司实施中期股息每股 7 港仙，末期股息拟派每股 7 港仙，合计每股派息 14 港仙，较 2024 年每股 12 港仙增长 16.7%。2025 年，亿胜生物科技的国际化战略取得成果，并不断扩大对外合作。旗下贝复舒 ® 已通过新加坡特别采用程序成功引入新加坡国家眼科中心，此里程碑标志产品首次进入中国以外地区，为未来在东南亚及全球市场推出奠定基础。此外，贝伐珠单抗 BLA 已获受理，前景广阔；而公司从 Mitotech 获得 SkQ1 滴眼液全球独家权益，能把握干眼症市场的庞大市场空间。国元国际表示，公司原有业务稳健增长，能提供较好的现金流，新产品贝伐珠单抗三期临床试验达到主要临床终点，该产品的国内以及海外市场空间广阔，随着创新药未来商业化顺利推进，将推动公司业绩上升。目前静态 PE 仅为 6.5 倍，价值低估，建议积极关注。重要披露：本文引用国元国际控股有限公司于 2026 年 3 月 24 日发表的研究报告内容。本资料仅供参考，不构成投资建议，投资有风险，请谨慎决策。 Copyright 2026 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

AALBORG, DENMARK AND MELBOURNE, AU, Mar 25, 2026 - (ACN Newswire via SeaPRwire.com) - The North Jutland technology company NanoNord has, in connection with the Royal Couple's state visit to Australia, secured an order for additional measurement equipment valued at between 160k - 240k AUD from the Australian deeptech pioneer ElectraLith. The order underscores the growing international potential for Danish measurement technology in the green transition.NanoNord was part of the business delegation during the state visit and seized the opportunity to strengthen its business with both existing and new customers in Australia. It is not the first time the Danish Royal Family has been close to NanoNord - the company was originally officially inaugurated by a then-young Crown Prince Frederik.Danish Technology Measures Lithium in Real TimeNanoNord's flagship technology, Tveskaeg, is an MR-based measurement instrument that enables precise real-time measurement of lithium and a range of other elements. The technology is wireless, uses neither chemicals nor disposable materials, and requires minimal calibration and maintenance - making it robust, green, and operationally reliable.ElectraLith uses Tveskaeg instruments as a central part of their groundbreaking DLE-R technology for lithium extraction. DLE (Direct Lithium Extraction) is a new and far more sustainable method for extracting lithium - a critical metal in the batteries powering the green transition. The full potential of the collaboration is up to DKK 10 million over the coming years, as ElectraLith rolls out its technology globally.The two companies connected in Melbourne during the Danish Industry reception 'An Evening in the Name of Business, Sport and Danish Dynamite,' and further strengthened ties during a meeting at ElectraLith's headquarters following the conclusion of the official business delegation.A Happy Customer on the Other Side of the Globe"Tveskaeg is an essential part of our DLE-R system and we are delighted with our partnership with Martin and the NanoNord team. Each DLE-R unit will include a Tveskaeg system to measure lithium and the order of additional units highlights its importance to our operations, particularly as we prepare for rapid global deployment to meet burgeoning demand lithium.Our existing two systems perform flawlessly and intuitively - so much so that our team has named them Forky and Hilda (after King Sweyn ‘Forkbeard' Tveskaeg and his wife). This is our second major order, in what we expect to be many."- Charlie McGill, CEO, ElectraLith"There is nothing better than visiting a customer on the other side of the globe and seeing our technology in use with happy customers like Charlie and his team. Our talented employees back at Skjernvej in Aalborg deserve the credit for the technology simply working and the customers being happy. That we can also bring home an order for additional instruments naturally makes me extra pleased."- Martin Mindorf, CCO, NanoNord"It is a great honour to be part of the historic state visit to Australia, and we are honoured by the attention from especially H.M. the Queen on this trip. The Queen quickly understood the potential of the technology in Australia and asked curiously about how Tveskaeg is used in connection with lithium extraction. NanoNord and ElectraLith are a great example of how our countries can work together, and there is great potential out here, particularly for the extraction of metals that are critical for the green transition. Beyond ElectraLith, we also have several exciting customers and prospects that we need to come back for."- Martin Mindorf, CCO, NanoNordAbout ElectraLithElectraLith is an American deeptech pioneer developing DLE-R - a proprietary electrochemical technology for lithium extraction and refining. The technology produces battery-grade lithium hydroxide or carbonate without water, chemicals, or waste, and can be powered by renewable energy.In December 2024, the company closed a materially oversubscribed Series A round of approximately USD 17 million with investors including Rio Tinto, Chevron, Marathon Petroleum, and In-Q-Tel. In 2026, ElectraLith was selected a Top Innovator by the World Economic Forum and has pilot projects planned in Australia, the United Kingdom, and Argentina.About NanoNordNanoNord was founded in 2001 by inventor Ole Nørgaard Jensen, who previously sold the Bluetooth pioneer company Digianswer to Motorola. The company develops and manufactures MR-based measurement equipment under the name Tveskaeg, used for applications including sodium measurement in food, lithium measurement in the mining industry, and nitrogen and phosphorus measurement in agriculture. Customers include global names such as Kraft-Heinz, Orkla, and Imerys. In the other industries, such as the food industry, NanoNord equipment eliminates the need for silver nitrate titration, and in several European countries, Tveskaeg technology is currently being tested for agricultural applications, where it has the potential to optimise the use of slurry, resulting in less groundwater pollution and better utilisation of nutrients.NanoNord is foundation- and family-owned, with the Lauritzen Foundation as a major investor, and continues to be led by founder Ole Nørgaard Jensen as CEO. In Australia, NanoNord is represented during the state visit by Martin Nørgaard Mindorf, CCO, the next generation of the family.Contact information:Martin MindorfCCOmm@nanonord.dk+4596341590Charlie McGillCEOcharles.mcgill@electralith.comSOURCE: NanoNord Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

丹麦奥尔堡和澳大利亚墨尔本, 2026年3月25日 - (亚太商讯 via SeaPRwire.com) - 北日德兰半岛科技公司NanoNord借丹麦王室夫妇对澳大利亚进行国事访问之机，成功获得澳大利亚深科技先驱ElectraLith价值16万至24万澳元的额外测量设备订单。该订单彰显了丹麦测量技术在绿色转型领域日益增长的国际潜力。NanoNord作为国事访问期间的商业代表团成员，借此良机加强了与澳大利亚现有及新客户的业务合作。这并非丹麦王室首次与NanoNord结缘——该公司最初正是由时任年轻的弗雷德里克王储正式揭幕的。丹麦技术实现锂元素实时测量NanoNord的旗舰技术Tveskaeg是一款基于核磁共振（MR）的测量仪器，能够对锂及其他多种元素进行精确的实时测量。该技术采用无线传输，不使用化学试剂或一次性耗材，且校准与维护需求极低，因此具备坚固耐用、环保及运行可靠的特点。ElectraLith将Tveskaeg仪器作为其突破性锂提取技术DLE-R的核心组件。DLE（直接锂提取）是一种新型且更具可持续性的锂提取方法——锂是推动绿色转型的电池中至关重要的金属。随着ElectraLith在全球范围内部署其技术，未来几年双方合作的潜在价值可达1000万丹麦克朗。两家公司于墨尔本举行的“丹麦工业招待会——以商业、体育和丹麦活力之名”活动中建立联系，并在官方商务代表团结束行程后，于ElectraLith总部举行的会议中进一步加深了合作关系。地球另一端的满意客户“Tveskaeg是我们DLE-R系统不可或缺的组成部分，我们非常高兴能与Martin及NanoNord团队建立合作伙伴关系。每台DLE-R设备都将配备Tveskaeg系统用于锂含量测定，此次追加订单充分彰显了该系统对我们运营的重要性，尤其在我们为满足激增的锂需求而准备快速全球部署之际。我们现有的两套系统运行完美且操作直观——甚至让团队给它们起了昵称‘福基’和‘希尔达’（取自‘叉胡子’斯文·特维斯卡格国王及其妻子的名字）。“这是我们收到的第二笔大额订单，预计未来还会有更多。”——查理·麦吉尔（Charlie McGill），ElectraLith首席执行官“没有什么比远赴地球另一端拜访客户，并看到像查理及其团队这样满意的客户正在使用我们的技术更令人欣慰的了。这项技术能够稳定运行并赢得客户满意，功劳应归于我们位于奥尔堡斯凯恩韦（Skjernvej）的才华横溢的员工们。能为公司再添一笔设备订单，自然让我倍感欣喜。”——马丁·明多夫，NanoNord首席商务官“能参与此次历史性的澳大利亚国事访问是莫大的荣幸，我们尤其荣幸此次行程中受到女王陛下的关注。女王迅速洞察了该技术在澳大利亚的潜力，并好奇地询问了Tveskaeg在锂提取中的具体应用。NanoNord与ElectraLith正是两国合作典范，澳大利亚蕴藏着巨大潜力，特别是在绿色转型所需关键金属的提取领域。除了ElectraLith，我们还有多家令人振奋的客户及潜在合作方，这正是我们必须再次造访的原因。”- 马丁·明多夫（Martin Mindorf），NanoNord首席商务官关于ElectraLithElectraLith是一家美国深科技先驱企业，致力于开发DLE-R——一种专有的锂提取与提炼电化学技术。该技术无需用水、化学品或产生废料，即可生产电池级氢氧化锂或碳酸锂，且可由可再生能源驱动。2024年12月，该公司完成了约1700万美元的A轮融资，认购额远超预期，投资方包括力拓、雪佛龙、马拉松石油和In-Q-Tel。2026年，ElectraLith被世界经济论坛评选为“顶级创新企业”，并计划在澳大利亚、英国和阿根廷开展试点项目。关于NanoNordNanoNord由发明家奥勒·诺加德·延森（Ole Nørgaard Jensen）于2001年创立，他此前曾将蓝牙先驱公司Digianswer出售给摩托罗拉。该公司以“Tveskaeg”为品牌名称，开发和制造基于MR技术的测量设备，应用领域包括食品中的钠含量测定、采矿业中的锂含量测定，以及农业中的氮磷含量测定。其客户包括卡夫亨氏（Kraft-Heinz）、奥克拉（Orkla）和伊美瑞斯（Imerys）等全球知名企业。在食品等其他行业，NanoNord的设备消除了对硝酸银滴定法的依赖；在欧洲多个国家，Tveskaeg技术目前正接受农业应用测试，有望优化液态肥的使用，从而减少地下水污染并提高养分利用率。NanoNord 是一家由基金会和家族共同持有的企业，Lauritzen 基金会是其主要投资者，公司仍由创始人 Ole Nørgaard Jensen 担任首席执行官。在澳大利亚，NanoNord 由首席商务官 Martin Nørgaard Mindorf（家族新一代成员）代表出席此次国事访问。联系方式：Martin Mindorf首席商务官mm@nanonord.dk+4596341590查理·麦吉尔首席执行官charles.mcgill@electralith.com来源：NanoNord Copyright 2026 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com